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uicide is a major public health issue in the West,
where it is among the top 10 causes of death.Throughout
world, suicide accounts for about 1 million deaths per
year,ie,1 death every 40 seconds,according to the World
Health Organization,
1 and constitutes a heavy familial,
social,and economic burden.
Some data concerning suicide are of major interest.First,
despite effort in prevention,suicide rates do not appear
be decreasing (Figure 1)
1 and, in many industrialized
countries,the number of people dying through suicide is
significantly higher than the number of people dying in
automobile accidents.Second,suicide rates in adolescents
and young adults increased in the last two or three
decades,and in many countries suicide mortality rates are
the third,or even the second,cause of death among young
people.
In view of these data,much effort has been made to study
the biology of suicide, and a central serotonergic dys-
function is possibly the most studied biological parame-
ter.Initial in vivo evidence comes from a study showing a
lower concentration of acid 5-hydroxyindoleacetic acid
(5-HIAA) in the cerebrospinal fluid (CSF) of depressed
suicidal patients compared with depressed nonsuicidal
patients.
2 Many have further confirmed this result, not
only in depression but also in schizophrenia and person-
ality disorder,
3 showing that lower 5-HIAA CSF concen-
tration is associated with suicidal behavior regardless of
psychiatric diagnosis.
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We carried out two studies to test the hypothesis that
altered central serotonergic function, as assessed by lower
prolactin (PRL) response to d-fenfluramine (D-FEN), is
more closely associated with suicidal behavior than a par-
ticular psychiatric diagnosis. A D-FEN test was performed
in 85 major depressed inpatients, 33 schizophrenic inpa-
tients, and 18 healthy controls. We showed that PRL
response to D-FEN is a marker of suicidality, regardless of
psychiatric disorder. We then examined the association
between the serotonin (5-hydroxytryptamine) receptor 
5-HT2A gene polymorphism (T102C) and suicide in a sam-
ple of Brazilian psychiatric inpatients (95 with schizo-
phrenia, 78 with major depression) and 52 healthy con-
trols. No differences were found in genotypic frequencies
across patients and controls. Overall, no differences were
found between patients with (n=66) and without (n=107)
a history of suicide attempt. We also compared patients
with a history of severe suicide attempts (lethality>3;
n=32) and patients without such a history (n=107), but
they did not exhibit different genotypic frequencies
either. These results show that the 5-HT2A gene polymor-
phism (T102C) may not be involved in the genetic suscep-
tibility to suicidal behavior.
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Neuroendocrine studies
A limitation of CSF studies is that they do not address the
question of whether overall serotonergic transmission in
the brain is decreased, since it is primarily a metabolic
measure;furthermore,these studies are rather invasive.
In this context,neuroendocrine tests offer a good alter-
native method of assessing central serotonergic function.
Various serotonin probes have been proposed in order to
obtain an index of the overall functional status of the cen-
tral serotonergic system,
4 but fenfluramine is the most
widely used.Both d-fenfluramine (D-FEN) and the race-
mate have been used, but the former is a more specific
serotonergic probe,lacking the dopaminergic and nora-
drenergic action of dl-fenfluramine.
5,6
D-FEN promotes release and inhibits uptake of sero-
tonin,increasing intrasynaptic levels of the neurotrans-
mitter.This action results in a dose-dependent response
of prolactin (PRL) release,which is thought to be medi-
ated by the serotonin (5-hydroxytryptamine,5-HT) recep-
tors 5-HT2A/5-HT2C
7 or by the 5-HT1A receptors,
8 or an
interaction between the two.Furthermore,D-FEN was
demonstrated to elicit an increase in PRL secretion com-
pared with control (saline) test in patients with depres-
sion, schizophrenia, or personality disorder.
9 Thus, a
blunted PRL response to D-FEN seems to reflect a deficit
in central serotonergic function.
There have been many studies of the hormonal response
to D-FEN in depressed patients but results are inconsis-
tent.Some authors
10-12 found a decreased PRL response
in patients with major depression compared with normal
control subjects,but others
13,14 could not replicate this find-
ing. However, these studies did not address whether
blunted PRL response correlates with suicidal behavior.
Kavoussi et al
15 analyzed a sample of outpatients without
a history of suicide attempt and did not find a difference
between normal volunteers and depressed patients in
PRL response to D-FEN.On the other hand,our previ-
ous study
16 showed a difference between depressed inpa-
tients and controls,but no clinical difference was observed
between depressed patients with reduced and normal
PRL response to D-FEN, except that the former had a
history of repeated suicide attempts.
To the best of our knowledge,there are only two studies
comparing the PRL response to D-FEN in patients with
schizophrenia and healthy subjects,
17,18 which showed an
increased PRL response to D-FEN in the former.Two
other studies compared patients with schizophrenia and
patients with depression,
9,12 showing conflicting results.
Whereas Duval et al
9 found no significant difference in
the hormonal response to D-FEN between the two
groups, Abel et al
12 found that PRL, but not cortisol,
response to D-FEN was significantly greater in schizo-
phrenia than in depression.To our knowledge,there have
not been any D-FEN studies that specifically address the
question of suicidal behavior in schizophrenia.
In view of these data,we carried out two studies to test
the hypothesis that altered central serotonergic function,
as assessed by lower PRL response to D-FEN, is more
closely associated with suicidal behavior than to a partic-
ular psychiatric diagnosis.
Neuroendocrine study in patients with 
major depression
A D-FEN test was performed,as previously described,
19
in 85 inpatients with major depression and 18 healthy con-
trols.Diagnosis was made by an experienced research psy-
chiatrist,who conducted a structured interview.
20The min-
imum severity criterion was defined as Hamilton Rating
Scale for Depression (HAM-D–17)
21 score of greater than
18 on the first 17 items.To be included patients could not
have other current comorbid Axis I psychiatric disorders,
such as anxiety disorders,substance abuse or dependence,
or a previous maniac or hypomaniac episode.They had to
be free of medication known to affect the serotonergic sys-
tem for at least 15 days,depending on the half-life of the
drug used, before the endocrine investigation and drug
washout was supervised in hospital.
Suicide history was assessed by an experienced psychia-
trist,blind to endocrine results,by means of a semistruc-
tured interview,and a review of medical records.Forty-
nine patients had a history of suicide attempt (mean±SD, Figure 1. Progression of global suicide rates between 1950 and 1995.
1
Men
Women
5
0
10
15
20
25
30
1950 1995
Year
R
a
t
e
 
(
p
e
r
 
1
0
0
 
0
0
0
)2±1.1 lifetime suicide attempts) and 36 did not.Patients
with a positive suicide history were then classified as
recent suicide attempters (n=26) if the suicidal act had
occurred during the current depressive episode and had
triggered their psychiatric hospitalization (D-FEN test
performed 11 to 37 days after most recent suicide
attempt); or past suicide attempters (n=23) if the most
recent suicide attempt had not occurred during the cur-
rent depressive episode (D-FEN test performed 5 to 86
months after most recent suicide attempt).
The Lethality Rating Scale
22 was used to measure the
degree of medical damage of the most lethal lifetime sui-
cide attempt.Medical damage is defined as the danger to
life from a suicide attempt.Following Malone et al,
23 we
scored no medical damage as zero and death as 8
(mean±SD,2.8±1.3 scored on the Lethality Rating Scale
in our sample).
Following other investigators,
24-27 we expressed the
changes in PRL after D-FEN (∆PRL) as PRL peak con-
centration value after D-FEN administration minus PRL
baseline concentration value.In the morning,PRL con-
centrations decrease owing to the normal circadian
rhythm.
28 Therefore, we used the values at t=0 min as
baseline levels.
Despite logarithmic or other transformations,the distrib-
ution of some data remained nonnormal (Kolmogorov-
Smirnov one-sample test for goodness of fit),thus non-
parametric statistical methods were used. Differences
between groups were tested by analysis of variance
(Kruskal-Wallis,H test) and,when the overall effect was
significant, the Mann-Whitney (U test) was used with
Bonferroni’s adjustment for three pairwise comparisons
when applicable.Correlations between quantitative vari-
ables were estimated using the Spearman rank coefficient
(ρ).Categorical data were analyzed using Fisher’s exact
test.All tests were two-tailed.Results were considered sig-
nificant when P≤0.05.
The three groups were comparable for age and sex distri-
bution,as well as for baseline hormone values (Table I).
The levels of PRL before and after D-FEN were not sig-
nificantly influenced by age, sex, or weight in the three
groups studied.There was no significant influence of the
baseline PRL or cortisol levels on ∆PRL values.Basal cor-
tisol levels were not different in the three groups and these
values did not differ with suicidal status.Moreover,∆PRL
values were comparable between premenopausal women
tested in the luteal phase and those tested in the follicular
phase,both in the controls and in the patients.Therefore,
the difference in ∆PRL values between depressed patients
with a suicide history and the two other subgroups could
not be explained by menstrual status.
Comparison of ∆PRL between depressed patients with-
out a suicidal history and control subjects showed no dif-
ference, but depressed patients with a suicidal history
exhibited a significantly lower ∆PRL when compared
with controls or depressed patients without a suicidal his-
tory (Figure 2).No differences were found between the
two groups of depressed patients in clinical or anamnes-
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Figure 2. The histograms (±SEM) represent ∆PRL (peak concentration
value of prolactin [PRL] after administration of d-fenfluramine
[D-FEN] minus PRL baseline concentration value) in 18 control
subjects and 33 patients with schizophrenia, classified accord-
ing to previous suicide attempt (SHSP, n=12) or no previous sui-
cide attempt (n=21). *P<0.0003 by Mann-Whitney two-tailed
U test, adjusted with Bonferroni’s method for multiple com-
parisons, for the difference between SHSP and controls.
**P<0.004 by Mann-Whitney two-tailed U test, adjusted with
Bonferroni’s method for multiple comparisons, for the differ-
ence between SHSP and NSHSP.
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Table I. Demographic characteristics and biological data for normal con-
trols and depressed patients according to their suicide history.
Values are means±SD. BPRL, basal prolactin concentration; ∆PRL,
peak concentration minus basal prolactin concentration; HAM-
D–17, Hamilton Rating Scale for Depression, 17-item version;
NSHDP, depressive patients with no suicidal history; SHDP, depres-
sive patients with a suicidal history. Mann-Whitney 2-tailed U test,
adjusted with Bonferroni’s method for multiple comparisons, for
the difference between: *P<0.02 SHDP vs controls; or **P<0.001
SHDP vs NSHDP.
Controls (n=18) NSHDP (n=36) SHDP (n=49)
Age (years) 36.8±11.4 40.8±10.1 40±10.9
Sex (M/F) 7/11 12/24 21/28
BPRL (µg/L) 15.6±7 15.8±9.4 12.5±8.5
∆PRL (µg/L) 6.6±5.3* 8.5±13.5** 2.5±5.5
HAM-D–17 - 23.5±5.3 25±4.8Research on serotonin and suicidal behavior - Corrêa et al Dialogues in Clinical Neuroscience - Vol 4 . No.4 . 2002
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tic data:age at illness onset in years (mean±SD,31.2±9.5
versus 31.6±10.9;P>0.9 by U test),length of the current
depressive episode in weeks (mean±SD;21.3±21.5 versus
19.7±14.9;P>0.9 by U test);number of previous episodes
(mean±SD, 4.2±4.9 versus 3.3±2.1; P>0.9 by U test);
Hamilton Anxiety (HAMA) scale scores (mean±SD,
19.7±7.1 versus 18.8±8;P>0.9 by U test);and distribution
of psychotic features (7 versus 5 patients with psychotic
features;P>0.9 by Fisher’s exact test).
Patients with a recent or past suicide attempt showed no
differences in baseline PRL or PRL response to D-FEN.
These values were not significantly influenced by age,
weight, or sex. Recent and past suicide attempter sub-
groups exhibited no statistical differences in number of
suicide attempts (mean±SD,1.9±1.2 versus 2.1±1;P>0.4
by U test) or lethality of the most lethal lifetime suicide
attempt (mean±SD, 2.9±1.2 versus 2.7±1.4 score on
Lethality Rating Scale;P>0.3 by U test).The other clin-
ical and anamnestic characteristics were also not statis-
tically different between these two subgroups, except
that recent suicide attempters presented a lower HAM-
D score than past suicide attempters (Table II).
In the whole sample of suicide attempt patients,we found
negative correlations between ∆PRL and (i) lethality of
the most lethal lifetime suicide attempt (ρ=-0.4;P<0.006;
n=49), and (ii) number of suicide attempts (ρ=-0.3;
P<0.04;n=49).Following Malone et al,
23 we subdivided
suicidal patients into those with high-lethality suicide
attempt (score ≥3) and those with low-lethality suicide
attempt (score <3),as measured by the Lethality Rating
Scale,considering the lethality of the most lethal lifetime
suicide attempt. The high-lethality subgroup (n=25)
showed significantly lower ∆PRL levels than the low-
lethality subgroup (mean±SD, 0.35±3.6 µg/L versus
4.7±6.4 µg/L;P<0.002 by U test).There was no statistical
difference in baseline PRL values between these groups
(mean±SD,12.9±9 µg/L versus 12.1±8 µg/L;P>0.7 by U
test).These values were not significantly influenced by
sex,age,or weight.The clinical and anamnestic charac-
teristics studied were not statistically different between
these two subgroups.
These results gave us some important information:
•We found that serotonergic dysfunction was associated
with suicidal behavior in depressed patients, but not
with depression itself.This could explain the divergent
results observed with this neuroendocrine test in pre-
vious studies, which did not specifically address the
question of suicidal behavior in the samples of
depressed patients.
• Patients with a history of recent suicide attempt did not
have a different PRL response to D-FEN from that of
patients having made a suicide attempt in the distant
past.This indicates that the medical damage itself did
not account for the reduced serotonergic function
observed in the suicide attempt group, and suggests
that this reduced serotonergic function may be a trait
marker of vulnerability to suicide.
•We found a negative correlation between PRL
response to D-FEN and number of suicide attempts
and lethality of the most lethal suicide attempt.In other
words,the lower the level of serotonergic function,the
more our depressed patients make suicidal attempts
over time and the more lethal they are,supporting the
idea that serotonin may be a stable marker of suicide
vulnerability.
The D-FEN test in schizophrenia
A D-FEN test,as previously described,
29 was performed
in 33 drug-free Diagnostic and Statistical Manual of
Mental Disorders,Fourth Edition (DSM-IV)
30 inpatients
with schizophrenia (12 with a suicide attempt,21 without)
and 18 hospitalized healthy controls.Since comorbidity of
depressive symptoms is frequent in schizophrenic
patients,
31,32 we did not include in our study patients pre-
senting a significant depressive symptomatology,exclud-
ing any patients with a HAM-D–17 greater than 15, to
reduce this eventual confounding factor.
Diagnosis was made by two experienced psychiatrists;
one conducted an unstructured interview and the other
used a structured instrument (Schedule for Affective
Disorders and Schizophrenia-Lifetime version).
20 The
final diagnoses were made by consensus of the two psy-
Table II. Demographic characteristics and biological data for depressed
patients with recent and past suicide history. Values are
mean±SD. BPRL, basal prolactin concentration; ∆PRL, peak con-
centration minus basal prolactin concentration; HAM-D–17,
Hamilton Rating Scale for Depression, 17-item version; RSHA,
history of recent suicide attempt; PSHA, history of past suicide
attempt. *P<0.05 analysis by Mann-Whitney test.
RSHA (n=26) PSHA (n= 23)
Age (years) 37.2±11.4 43.2±9.7
Sex (M/F) 12/14 9/14
BPRL (µg/L) 14±8.7 10.8±8.1
∆PRL (µg/L) 2.9±5 2±6.1
HAM-D–17 23.5±3.7 26.8±5.4*chiatrists,blinded to the endocrine data.Suicide history
attempt assessment and statistical analysis were con-
ducted following the same procedures described above
for depressed patients.
The schizophrenic patients as a whole showed no signifi-
cantly different baseline PRL values (13.9±7 µg/L versus
15.6±7 µg/L; P>0.8 by the U test) when compared with
healthy controls.However,DPRL was significantly lower
in this group when compared with normal volunteers
(2±6.1 µg/L versus 6.6±5.3 µg/L;P<0.01 by the U test).This
difference was mainly accounted for by the significantly
lower PRL levels in suicidal patients, since a subgroup
analysis showed that patients with schizophrenia and a sui-
cide history exhibit lower levels of PRL in response to 
D-FEN compared with patients with schizophrenia with-
out such a history,and also compared with healthy con-
trols. No difference in ∆PRL levels was found between
patients with schizophrenia without a suicide history and
controls.
Healthy controls and patients with schizophrenia, sub-
grouped by suicide history, presented no difference in
demographic characteristics or baseline hormonal values
as shown in Table III.The patients with schizophrenia and
a suicide attempt history showed no demographic,clini-
cal, or anamnestic differences compared with patients
without such a history. Age in years (30.4±11.1 versus
32±11.7; P>0.9 by U test), weight (61.3±8.8 kg versus
62.2±9.2 kg;P>0.75 by U test),age of illness onset in years
(21.3±4.9 versus 24.9±8.7; P>0.3 by U test), number of
previous hospitalizations (3.0±1.7 versus 2.8±1.9;P>0.5
by U test), and distribution of schizophrenia subtypes
(paranoid 5 versus 11;undifferentiated 3 versus 2;and dis-
organized 4 versus 8) were not statistically different
between patients with schizophrenia with or without a
suicidal history. Psychopathological data (HAM-D–17
and Brief Psychiatric Rating Scale [BPRS]) was also eval-
uated. No differences in HAM-D–17 scores or in the
BPRS total or factor scores were found between patients
with or without a history of suicide attempt (Table IV).
Patients with a recent suicide attempt (n=5) exhibited
comparable basal and post-fenfluramine hormonal levels
when compared with patients with a past suicide attempt
(n=7).Demographic and clinical characteristics were sim-
ilar between these two subgroups (Table V).
These results show us that:
• A serotonergic dysfunction was associated with suicidal
behavior in patients with schizophrenia, but not with
schizophrenia itself.
• Patients with a history of a recent suicide attempt did not
have a different PRL response to D-FEN to patients
with a suicide attempt in the distant past.This indicates
that the injury itself did not account for the reduced sero-
tonergic function observed in the suicide attempt group
Basic research
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Table III. Demographic characteristics and biological data for normal con-
trols and patients with schizophrenia according to their suicide
history. Values are expressed as means±SD. BPRL, basal prolactin
concentration; ∆PRL indicates peak concentration minus basal
prolactin concentration; SHSP, schizophrenic patients with a sui-
cide attempt history; NSHSP, schizophrenic patients without a
suicide attempt history. Mann-Whitney 2-tailed U test, adjusted
with Bonferroni’s method for multiple comparisons, for the dif-
ference between: *P<0.04 SHSP vs NSHSP; or **P<0.0003 SHSP
vs controls.
Controls (n=18) SHSP (n=12) NSHSP (n=21)
Age (years) 36.8±11.4 30.4±11.1 32±11.7
Sex (M/F) 7/11 5/7 12/9
BPRL 15.6±7 16.9±8.6 12.2±5.5
∆PRL 6.6±5.3* -1.8±4.4 4.2±5.8**
Table V. Demographic characteristics and biological data for patients with
schizophrenia with recent and past suicide history. Values are
means±SD. BPRL, basal prolactin concentration; ∆PRL, peak con-
centration minus basal prolactin concentration; BPRS, Brief
Psychiatric Rating Scale; HAM-D–17, Hamilton Rating Scale for
Depression, 17-item version; RSHA, history of recent suicide
attempt; PSHA, history of past suicide attempt.
RSHA (n=5) PSHA (n=7) P
Age (years) 31.3±12.5 29.2±10.2 NS
Sex (M/F) 3/4 2/3 NS
BPRL (µg/L) 15.5±8.6 18.7±9.1 NS
∆PRL (µg/L) -1.3±4.1 -2.5±5.2 NS
BPRS 52.8±9.7 49.8±10.5 NS
HAM-D–17 11.7±1.9 12.4±3.1 NS
Table IV. Psychopathological data for patients with schizophrenia accord-
ing to their suicide history. Values are expressed as means±SD.
HAM-D–17, Hamilton Rating Scale for Depression, 17-item ver-
sion; BPRS, Brief Psychiatric Rating Scale; SHSP, patients with
schizophrenia and a suicide attempt history; NSHSP, patients with
schizophrenia but no suicide attempt history.
SHSP NSHSP P
n 12 21 NS
HAM-D–17 12±2.4 10.4±3 NS
BPRS 50.6±10 47.6±7 NS
Delusion dimension 11.3±4.2 11.4±4.4 NS
Anxiodepressive dimension 6.4±2.2 5.3±1.8 NS
Hebephrenic dimension 10±4.8 9.1±4.4 NS
Paranoid dimension 8.5±2.5 8.1±2.6 NSResearch on serotonin and suicidal behavior - Corrêa et al Dialogues in Clinical Neuroscience - Vol 4 . No.4 . 2002
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suggesting that a lower serotonergic function may be a
trait marker for suicidality in schizophrenia too.
• We failed to replicate previous studies showing that a
serotonergic dysfunction may be associated with more
lethal suicide attempts.
19,23A type β error is probably the
reason for this discrepancy,in view of our small sample
(n=12) of suicide attempt patients.
Molecular approach
As described above,serotonergic dysfunction in the brain
has been reported to be involved in suicidal behavior
independently of the presence of a specific psychiatric
disorder.There is much evidence suggesting that suicidal
behavior is,at least partially,genetically determined,as
shown by many familial, twin, and adoption studies.A
search for the gene,or more probably the genes,involved
in suicidal behavior could involve a investigation of the
entire genome.Current debate concerns whether there is
a relationship between genetic polymorphisms with inter-
mediate phenotypes, such as impulsivity, psychomotor
abnormalities, and aggression, and other biological
abnormalities including specific gene products.
Serotonergic function is a complex equation depending
on the functional state of enzymes, reuptake protein,
and about 15 different receptors. However, since 
D-FEN–induced increase in PRL plasma levels is medi-
ated by 5-HT2A,5-HT2C,or 5-HT1A receptors,the genes
for these receptors,as well as others related to important
steps in serotonergic function,like the serotonin trans-
porter and tryptophan hydroxylase,are also candidates
associated with suicidal behavior.
Several postmortem studies have reported an increased 
5-HT2A binding in prefrontal cortex in suicide victims,
when compared with controls,which makes 5-HT2A an
interesting candidate gene in suicidal behavior.However,
investigations in unselected suicide completers did not
suggest any evidence of association between genetic vari-
ation at this gene when tested for the T102C and A1438G
polymorphisms,as well as the Thr25Asp,His542Tyr,and
C516T polymorphisms
33 and completed suicide, even
though evidence was found for a relationship between
genetic variation at the T102C and A-1438G loci and 5-
HT2A binding in the prefrontal cortex.
34 Negative associ-
ation results were also found in other studies that inves-
tigated suicide completers with major depression
35,36 and
suicide attempters.
37 However,two other studies reported
positive results. Zhang et al
38 investigated the T102C
polymorphism and found a slight difference in genotype
distribution in 15 subjects with a history of suicide
attempt and 87 subjects without suicidal behavior.The
same polymorphism was investigated in suicidal ideation
in patients with major depression and an increase in the
C (T102C) allele in suicidal ideation was found.
39Thus,
studies on Caucasian populations have not been conclu-
sive.Bjork et al
40 investigated whether this polymorphism
could be specifically related to impaired impulse control
in adults recruited from the community.They reported
that the 102C/102C genotype was jointly associated with
a greater incidence of past mood disorder or substance
use disorder, as well as significantly more commission
errors on CPT (continuous performance test) compared
with the 102T/102C and 102C/102C genotypes,suggest-
ing that the T102C 5-HT2A receptor polymorphism might
be a marker for impaired behavior in the context of psy-
chiatric disorder history.
40Taking all that into account,we
examined the role of T102C polymorphism of the 5-
HT2A gene in a selected Brazilian population.
A total of 225 unrelated subjects were enrolled after a
full explanation of this study and signing an informed
consent.This study was approved by University’s Ethics
Committee.Patient eligibility was ascertained after con-
secutive admissions at two Belo Horizonte hospitals
(Hospital Santa Maria and Clínica Pinel) meeting the
DSM-IV
30 diagnostic criteria based on a structured inter-
view (MINI-PLUS). Only patients with a diagnosis of
recurrent major depression (n=78) or schizophrenia
(n=95) without any other current comorbid Axis I disor-
der were selected.Healthy controls were students,nurses,
and staff members (n=52), all free of psychiatric and
medical illness,with no family history of Axis I psychi-
atric disorder in first-degree relatives.
A review of medical records was performed and suicide
history was independently assessed, using a semistruc-
tured interview.
19,29 Sixty-six patients had a history of sui-
cide attempts (2.5±1.2,mean±SD).The Lethality Rating
Scale, adapted as previously described,
19,29 was used to
measure the degree of medical damage of the most lethal
lifetime suicide attempt.
DNA was isolated from lymphocytes using routine pro-
cedures.Polymerase chain reaction (PCR) amplification
of the HT2A/T102C region containing the polymorphic
site produced a 372-bp fragment.This was digested with
the restriction enzyme HpaII.The uncut product corre-
sponded to the nucleotide sequence TCT. Digested
products with 216 and 126 bp corresponded to TCCallele as described elsewhere.
35 Chi-square tests were
used to compare frequencies.
Patients and controls were not different in terms of demo-
graphic characteristics like age and sex.Moreover,no dif-
ferences were observed in genotypic frequencies across
these groups (Table VI).
No allele differences (TT, TC, or  CC) were found
between patients with a suicide attempt history (n=66)
and without (n=107):TT (18 [27.3%],30 [28%]);TC (35
[53%],55 [51.4%]);CC (13 [19.7%],22 [20.5%]).Patients
with a history of severe suicide attempts (lethality>3;
n=32) and patients without such a history (n=107) also
did not exhibit a statistically significant difference in
genotypic frequencies:TT (12 [37.5%],30 [28%]);TC (17
[53%],55 [51.4%]);CC (3 [9.4%],22 [20.5%]).
Our study comprised a rather homogeneous sample of
inpatients with major depression or schizophrenia, as
assessed with structured instruments to evaluate diagno-
sis and suicide attempt history.This is important since sui-
cide history can be underevaluated with simple clinical
interviews.Overall,we did not find differences between
patients with and without a suicide attempt history,
regardless of its severity.
More work in this area is of great value.We cannot reli-
ably exclude a type II error accounting for the negative
association.It may be possible that 5-HT2A has a role in
suicide susceptibility,but the number of subjects in this
study did not afford enough power to detect this effect.
There seem to be more 5-HT2A receptors in suicide vic-
tims
40 and a functional polymorphism involving the 
promoter region that affect the gene expression may
explain this fact.Interestingly,Ohara et al
41 found that the
-1438G/A promoter polymorphism was in linkage dise-
quilibrium with T102C.
We are currently investigating genetic polymorphisms in
other candidate genes of the serotonergic function,like
the receptors 5-HT1A and 5-HT2C,the enzyme tryptophan
hydroxylase and the membrane serotonin transporter. ❏
The molecular study has the financial support of CNPq-550395016.
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Table VI. Demographic and genotypic differences among groups.
Schizophrenia Depression Controls
n9 5 7 8 5 2
Sex (M/F) 50/45 38/40 25/27
TT 28 (29.5%) 20 (25.7%) 15 (28.8%)
TC 47 (49.5%) 43 (55.1%) 27 (52%)
CC 20 (21%) 15 (19.2%) 10 (19.2%)
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Investigación sobre la serotonina y la 
conducta suicida: aproximaciones 
neuroendocrina y molecular
Nosotros realizamos dos estudios para probar la
hipótesis de la alteración de la función serotoni-
nérgica central –la cual se evalua mediante la
menor respuesta de prolactina (PRL) a la d-fenflu-
ramina (D-FEN)– que está más estrechamente aso-
ciada con la conducta suicida que con cualquier
otro diagnóstico psiquiátrico. Se realizó una prueba
de D-FEN en 85 pacientes hospitalizados con depre-
sión mayor, 33 pacientes hospitalizados esquizofré-
nicos y 18 controles normales. Nosotros mostramos
que la respuesta de PRL a D-FEN es un marcador de
suicidalidad, independiente del diagnóstico psi-
quiátrico. Luego examinamos la asociación entre el
polimorfismo del gen del receptor de serotonina 
(5-hidroxitriptamina) 5-HT2A (T102C) y el suicidio en
una muestra de pacientes psiquiátricos brasileños
hospitalizados (95 con esquizofrenia, 78 con depre-
sión mayor) y 52 controles sanos. No se encontra-
ron diferencias en las frecuencias de los genotipos
entre los pacientes y controles. En conjunto, no se
encontraron diferencias entre pacientes con (n=66)
y sin (n=107) historia de intentos suicidas. Nosotros
también comparamos pacientes con historia de
intentos suicidas severos (letalidad >3, n=32) y
pacientes sin tal historia (n=107) y no se encontra-
ron frecuencias genotípicas diferentes entre ellos.
Estos resultados demuestran que el polimorfismo
del gen de 5-HT2A (T102C) no puede estar involu-
crado en la susceptibilidad genética a la conducta
suicida.
Recherches sur la sérotonine et le 
comportement suicidaire : approches 
neuroendocrinienne et moléculaire
Nous avons mené deux études pour vérifier l’hypo-
thèse selon laquelle l’altération de la  fonction séro-
toninergique centrale, dont le stigmate est une
réponse plus basse de la prolactine (PRL) à la d-fen-
fluramine (D-FEN), serait plus étroitement associée
à un comportement suicidaire qu’à un diagnostic
psychiatrique particulier. Un test D-FEN a été réalisé
chez des patients hospitalisés, dont 85 étaient
atteints de dépression majeure et 33 de schizo-
phrénie, et 18 témoins en bonne santé. Nous avons
montré que la réponse de la PRL à la D-FEN est un
marqueur de risque suicidaire, indépendamment de
toute pathologie psychiatrique. Nous avons alors
examiné l’association entre le polymorphisme géné-
tique (T102C) du récepteur 5-HT2A à la sérotonine
(5-hydroxytryptamine) et le suicide dans un échan-
tillon de patients brésiliens hospitalisés atteints de
pathologie psychiatrique (95 schizophrènes, 78
atteints de dépression majeure) et 52 témoins en
bonne santé. Aucune différence de fréquences
génotypiques n’a été observée entre les patients et
les témoins. Au total, aucune différence n’a été
retrouvée entre les patients avec (n = 66) ou sans 
(n = 107) antécédent de tentative de suicide. Nous
avons aussi comparé les patients ayant un antécé-
dent grave de tentative de suicide (mortalité > 3 ;
n = 32) et les patients sans antécédent de ce type 
(n = 107), mais eux non plus ne présentaient pas de
fréquences génotypiques différentes. Ces résultats
montrent que le polymorphisme génétique du 
5-HT2A (T102C) peut ne pas être impliqué dans la
sensibilité génétique au comportement suicidaire.
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